Virtu Financial LLC Invests $110,000 in Health Catalyst, Inc. (NASDAQ:HCAT)

Virtu Financial LLC acquired a new stake in Health Catalyst, Inc. (NASDAQ:HCAT) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,497 shares of the company’s stock, valued at approximately $110,000.

Other large investors have also bought and sold shares of the company. Palogic Value Management L.P. acquired a new stake in shares of Health Catalyst in the fourth quarter valued at about $2,262,000. Intech Investment Management LLC raised its holdings in Health Catalyst by 59.7% during the 4th quarter. Intech Investment Management LLC now owns 28,386 shares of the company’s stock worth $201,000 after purchasing an additional 10,611 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Health Catalyst by 93.7% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 254,762 shares of the company’s stock worth $1,801,000 after purchasing an additional 123,230 shares during the period. Essex Investment Management Co. LLC boosted its stake in shares of Health Catalyst by 19.4% in the 4th quarter. Essex Investment Management Co. LLC now owns 295,112 shares of the company’s stock valued at $2,086,000 after purchasing an additional 47,951 shares during the last quarter. Finally, AlphaQuest LLC increased its position in shares of Health Catalyst by 1,989.8% during the fourth quarter. AlphaQuest LLC now owns 87,395 shares of the company’s stock worth $618,000 after buying an additional 83,213 shares during the period. 85.00% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. KeyCorp raised shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target on the stock in a research report on Wednesday, January 8th. Piper Sandler decreased their target price on Health Catalyst from $12.00 to $8.00 and set an “overweight” rating for the company in a research note on Tuesday, February 11th. Stephens dropped their price target on Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 6th. Wells Fargo & Company reduced their price objective on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a research report on Tuesday, January 21st. Finally, Citigroup dropped their target price on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $9.27.

Health Catalyst Stock Down 1.1 %

Shares of NASDAQ HCAT opened at $4.55 on Monday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. Health Catalyst, Inc. has a 1 year low of $3.76 and a 1 year high of $9.24. The stock has a market capitalization of $319.46 million, a P/E ratio of -3.37 and a beta of 1.41. The company has a 50-day moving average price of $5.03 and a 200-day moving average price of $6.85.

Insider Buying and Selling at Health Catalyst

In other Health Catalyst news, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $7.51, for a total transaction of $39,119.59. Following the transaction, the chief operating officer now owns 91,253 shares of the company’s stock, valued at $685,310.03. This trade represents a 5.40 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Benjamin Landry sold 13,827 shares of the stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $4.55, for a total value of $62,912.85. Following the sale, the general counsel now directly owns 160,437 shares of the company’s stock, valued at $729,988.35. The trade was a 7.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 56,530 shares of company stock worth $299,572. Corporate insiders own 2.50% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.